UPDATE: Earlier today, we announced preliminary data from our ongoing Phase 1/2 study with @BioNTech_Group for a SARS-CoV-2 mRNA-based #vaccine candidate: https://t.co/6N42aJDzWM $PFE #COVID19 https://t.co/7eQ07DTkDI